Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light (SPUTNIK-LIGHT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04741061
Recruitment Status : Recruiting
First Posted : February 5, 2021
Last Update Posted : February 21, 2021
Sponsor:
Collaborators:
Russian Direct Investment Fund
CRO: iPharma
Government of the city of Moscow
Information provided by (Responsible Party):
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

Tracking Information
First Submitted Date  ICMJE February 2, 2021
First Posted Date  ICMJE February 5, 2021
Last Update Posted Date February 21, 2021
Actual Study Start Date  ICMJE February 19, 2021
Estimated Primary Completion Date December 31, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 4, 2021)
  • Incidence and severity of adverse events in study subjects [ Time Frame: through the whole study, an average of 180 days ]
    Incidence and severity of AEs and SAEs during the subject's participation in the study
  • Percentage of study subjects with COVID-19 cases developed after vaccination [ Time Frame: through the whole study, an average of 180 days ]
    Percentage of study subjects with COVID-19 cases developed after vaccination with the Sputnik-Light vector vaccine as compared with placebo
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 4, 2021)
  • Humoral immunogenicity (Quantitative IgG antibodies to SARS-CoV-2 S Protein) [ Time Frame: at days 0, 42, 180 ]
    Geometric mean titer (GMT) levels of Quantitative IgG antibodies
  • Humoral immunogenicity (IgG SARS-CoV-2 N-antibodies) [ Time Frame: at days 0, 42, 180 ]
    Percentage of study subjects who have a post-treatment response as measures with Qualitative IgG SARS-CoV-2 N-antibodies
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light
Official Title  ICMJE A Phase III, Randomized, Double-blind, Placebo-controlled International Multicenter Study to Evaluate Efficacy, Immunogenicity and Safety of the Sputnik-Light Vector Vaccine in the Parallel Assignment of the Subjects in Prophylactic Treatment for SARS-СoV-2 Infection
Brief Summary The study Global sponsor is planning several parallel studies of Sputnik-Light vector vaccine across the globe in United Arab Emirates, Russia and possibly in other countries in case of confirmation associated with the same medical product under similar protocols. The key objective of this study is to be conducted in several parallel studies of the same vaccine above the other countries. Using similar protocols on a portfolio basis of studies let us collect data for Efficacy, Immunogenicity, Safety and Tolerability confirmation of the Sputnik-Light vaccine.
Detailed Description

This study is randomized, double-blind (blinded for the study subject and investigators), placebo-controlled international multicenter study in the parallel assignment of the subjects to assess efficacy, immunogenicity and safety of the Sputnik-Light vector vaccine in adults in the SARS-СoV-2 infection prophylactic treatment

The subjects will be randomized into two groups in the ratio of 1:3; a control group (1500 subjects receiving placebo) and a study group (4500 subjects receiving the Sputnik-Light vector vaccine against the SARS-СoV-2-induced COVID19 infection).

For the evaluation of immunogenicity an unbalanced design is adopted of the placebo and vaccinated group at a 1:3 ratio. Subsequently the number of subjects in Subgroup A tested will be 1076 subjects, distributed as follows: 269 in the placebo group and 807 in the vaccinated group, also randomized into two groups in the ratio of 1:3 who will attend for assessment of immunogenicity compared to baseline.

Each subjects will participate in the trial for approximately 6 months after the first dose of the study vaccine/placebo and will have at least tree on-site visits, including a screening visit to the study clinical site during the study period and several observation Phone Call/ Tele-consultation visits during the study

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
randomized, double-blind (blinded for the study subject and investigators), placebo-controlled
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Condition  ICMJE COVID-19 Prevention
Intervention  ICMJE
  • Biological: Sputnik Light

    Sputnik-Light vector vaccine:

    Active substance: recombinant adenovirus serotype 26 particles containing the SARS-CoV-2 protein S gene, in the amount of (1.0±0.5) х 1011 particles per dose.

  • Other: Placebo
    Placebo
Study Arms  ICMJE
  • Active Comparator: Sputnik Light Vaccine
    study group (4500 receiving the Sputnik-Light vector vaccine) against the SARS-СoV-2-induced coronavirus infection.
    Intervention: Biological: Sputnik Light
  • Placebo Comparator: Placebo Group
    control group (1500 subjects receiving placebo)
    Intervention: Other: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: February 4, 2021)
6000
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE January 31, 2022
Estimated Primary Completion Date December 31, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Agree to sign the study informed consent form (ICF) before performing any study specific procedure
  2. Adults ≥ 18 years old
  3. Negative COVID-19 PCR test result at the screening visit and negative immunochromatographic SARS-CoV-2 antigen rapid-test result at the enrolment
  4. Consent for using effective methods of contraception during the study
  5. No evidence of vaccine-induced reactions or complications after receiving immunobiological products in medical history
  6. No acute infectious and/or respiratory diseases within at least 14 days before the enrolment

Exclusion Criteria:

  1. Any previous vaccination/immunization (within 30 days before the enrollment) and any planned vaccination within 30 days after enrollment
  2. Any previous or planning COVID-19 vaccination with any other Regulatory approved vaccine
  3. Positive SARS-CoV-2 screening result obtained by PCR (at screening)
  4. Administration of steroids (except hormonal contraceptives) and/or immunoglobulins or other blood products therapy not finished 30 days before the enrollment
  5. Pregnancy or lactation
  6. Acute coronary syndrome or stroke suffered less than one year before study enrollment
  7. Tuberculosis, chronic systemic infections associated with Immunocompromised subjects in medical history
  8. History of severe allergic reaction to drug or vaccine (anaphylactic shock, Quincke's edema, and other life-threatening allergic reactions), acute exacerbation of allergic diseases on screening and vaccination day
  9. Chronic autoimmune disease and system collagenases in medical history
  10. Organ transplantation and immunosuppressive therapy
  11. Immunosuppressive therapy and corticosteroid system therapy within 3 months before the enrollment
  12. Subjects with malignant neoplasms within 5 years before the enrollment
  13. Splenectomy in the past medical history
  14. Neutropenia (absolute neutrophil count <1,000 mm3 agranulocytosis, significant blood loss, severe anemia (hemoglobin <80 g/L), immunodeficient disease in the medical history within 6 months before the enrollment
  15. The active form of a disease caused by the human immunodeficiency virus, syphilis, hepatitis B, or C
  16. Acute Kidney injury or dialysis
  17. Anorexia or dysnutrition
  18. Tattoos at the injection site (deltoid muscle area), which in the medical opinion of the investigator does not allow assessing the local response to the vaccine/placebo
  19. Alcohol or Drug abuse in medical history
  20. Participation in other interventional clinical trial within the previous 90 days prior to vaccination and over duration of the trial
  21. Any other condition that the investigator considers as a barrier to the trial completion as per the protocol
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 111 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Elena Merkulova +7 (495) 276 11 43 ext 495 eam@ipharma.ru
Listed Location Countries  ICMJE Russian Federation
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04741061
Other Study ID Numbers  ICMJE 01 - Sputnik Light - 2021
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Study Sponsor  ICMJE Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Collaborators  ICMJE
  • Russian Direct Investment Fund
  • CRO: iPharma
  • Government of the city of Moscow
Investigators  ICMJE Not Provided
PRS Account Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Verification Date February 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP